Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.
A. Blom Fily(Hôpital Ambroise-Paré), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Marie-Noelle Solbes(Merck KGaA, Darmstadt (Germany)), Célèste Lebbé(Inserm), E. Maubec(Inserm), B van Hille(Merck Serono S.A.S. (France)), F. Aubin(Centre Hospitalier Universitaire de Besançon), P. Joly(Inserm), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), I. Kachaner(Pfizer (France)), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), C. Lenormand(Hôpitaux Universitaires de Strasbourg), Laurent Mortier, G. Quéreux(Nantes Université), Caroline Robert(Institut Gustave Roussy), C. Cahuzac(Merck Serono S.A.S. (France)), M. Samimi(Centre Hospitalier Universitaire de Tours), Laura Luciani(Merck Serono S.A.S. (France)), H. Miotti(IQVIA (France))
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k